MedTrace Logo

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

NCT01169753 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-12-08

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if Nuvigil (armodafinil) can help to control fatigue in patients with CML. The safety of this drug will also be studied.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Placebo

Oral tablet every morning for 2 weeks

DRUG

Armodafinil

Three 50 mg tablets orally every morning for 2 weeks.

Sponsors & Collaborators

  • Cephalon

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Carmen Escalante, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01169753 on ClinicalTrials.gov